CN103845724A - 预防或治疗心力衰竭的方法 - Google Patents

预防或治疗心力衰竭的方法 Download PDF

Info

Publication number
CN103845724A
CN103845724A CN201410049107.5A CN201410049107A CN103845724A CN 103845724 A CN103845724 A CN 103845724A CN 201410049107 A CN201410049107 A CN 201410049107A CN 103845724 A CN103845724 A CN 103845724A
Authority
CN
China
Prior art keywords
arg
lys
phe
dmt
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410049107.5A
Other languages
English (en)
Chinese (zh)
Inventor
黑兹尔·H·司徒
彼得·S·拉宾诺维奇
戴道福
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Cornell University
Original Assignee
University of Washington
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Cornell University filed Critical University of Washington
Publication of CN103845724A publication Critical patent/CN103845724A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201410049107.5A 2009-10-05 2010-10-04 预防或治疗心力衰竭的方法 Pending CN103845724A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24868109P 2009-10-05 2009-10-05
US61/248,681 2009-10-05
US28948309P 2009-12-23 2009-12-23
US61/289,483 2009-12-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2010800551907A Division CN102711785A (zh) 2009-10-05 2010-10-04 预防或治疗心力衰竭的方法

Publications (1)

Publication Number Publication Date
CN103845724A true CN103845724A (zh) 2014-06-11

Family

ID=43823652

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800551907A Pending CN102711785A (zh) 2009-10-05 2010-10-04 预防或治疗心力衰竭的方法
CN201410049107.5A Pending CN103845724A (zh) 2009-10-05 2010-10-04 预防或治疗心力衰竭的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2010800551907A Pending CN102711785A (zh) 2009-10-05 2010-10-04 预防或治疗心力衰竭的方法

Country Status (7)

Country Link
US (7) US20110082084A1 (enExample)
EP (5) EP3603658B1 (enExample)
JP (6) JP2013506696A (enExample)
CN (2) CN102711785A (enExample)
CA (1) CA2776581C (enExample)
HK (1) HK1217293A1 (enExample)
WO (1) WO2011044044A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025044786A1 (zh) * 2023-08-28 2025-03-06 南京医科大学 一类肽及其衍生物和应用

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9306796B1 (en) 2008-03-18 2016-04-05 Mcafee, Inc. System, method, and computer program product for dynamically configuring a virtual environment for identifying unwanted data
CN105031605A (zh) * 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
US20110082084A1 (en) 2009-10-05 2011-04-07 Szeto Hazel H Methods for the prevention or treatment of heart failure
AU2010339414A1 (en) * 2009-12-31 2012-07-19 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
WO2013149172A1 (en) * 2012-03-30 2013-10-03 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
WO2014066419A2 (en) * 2012-10-22 2014-05-01 Stealth Peptides International, Inc. Methods for reducing risks associated with heart failure and factors associated therewith
CN110339339A (zh) * 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
CN115990242A (zh) * 2013-03-01 2023-04-21 康德生物医疗有限公司 预防或治疗巴斯综合征的方法和组合物
EP3586864A1 (en) * 2013-05-14 2020-01-01 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricle remodeling
EP3003312A1 (en) * 2013-05-28 2016-04-13 Dana-Farber Cancer Institute, Inc. Bet inhibition therapy for heart disease
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US20160166633A1 (en) * 2013-08-02 2016-06-16 Stealth Bio Therapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
WO2016004441A1 (en) * 2014-07-03 2016-01-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of acute myocardial infarction injury
US10368774B2 (en) 2015-07-30 2019-08-06 Medtronic, Inc. Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event
CN116196389A (zh) * 2016-01-06 2023-06-02 康德生物医疗有限公司 用于预防和治疗杜氏肌肉萎缩症的方法和组合物
WO2017151886A1 (en) * 2016-03-02 2017-09-08 Stealth Biotherapeutics Corp Methods and compositions for the treatment and prevention of pulmonary arterial hypertension
AU2017249218B2 (en) 2016-04-11 2020-08-27 Arcuate Therapeutics, Inc. Chiral peptides
WO2018005990A2 (en) * 2016-07-01 2018-01-04 Marshall University Research Corporation Compositions and methods for treating uremic cardiomyopathy
EP3612178A4 (en) * 2017-04-21 2021-01-13 Northeast Ohio Medical University VASODILATERS FOR THE TREATMENT OF HEART FAILURE
EP3890765B1 (en) * 2018-12-06 2023-09-20 Stealth BioTherapeutics Inc. D-arg-2'6'-dmt-lys-phe-nh2 for use in treating or preventing sengers syndrome
CN112111003B (zh) * 2019-06-20 2022-02-11 中国农业大学 含有me序列的一类新型抑制血小板聚集和抗血栓形成寡肽
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
CA3187301A1 (en) * 2020-06-17 2021-12-23 Stealth Biotherapeutics Inc. Methods and compositions for the treatment of muscular dystrophy
KR102666922B1 (ko) 2020-09-09 2024-05-20 소셜 프로핏 네트워크 미토콘드리아에 비오틴의 전달을 위한 방법 및 조성물
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248808A1 (en) * 2003-02-04 2004-12-09 Szeto Hazel H. Methods for preventing mitochondrial permeability transition
WO2009100363A2 (en) * 2008-02-07 2009-08-13 Cornell University Methods for preventing or treating insulin resistance

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4732898A (en) * 1986-04-29 1988-03-22 Warner-Lambert Company 2-(2-aryl-2-oxoalkylidene) analogs of-3,5-pyridinedicarboxylic acid dialkyl esters useful for treatment of cardiovascular disorders
ES2085865T3 (es) * 1988-06-30 1996-06-16 Astra Ab Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean.
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5747641A (en) * 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
DE69630918T2 (de) * 1995-06-09 2004-10-28 Hisamitsu Pharmaceutical Co., Inc., Tosu Matrix für Iontophorese
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
WO1997016169A1 (en) * 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
JP2002505077A (ja) * 1997-12-10 2002-02-19 ワシントン大学 抗病原体システムおよびその使用方法
EP1071414A1 (en) * 1998-04-24 2001-01-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6503713B1 (en) * 1999-10-04 2003-01-07 University Of Medicine And Dentistry Of New Jersey Methods for identifying RNA binding compounds
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
US7498297B2 (en) * 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
IT1318370B1 (it) * 2000-12-21 2003-08-25 Tonino Bombardini Metodo e dispositivo per la diagnosi e la terapia dello scompensocardiaco cronico.
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
MXPA04003040A (es) * 2001-10-01 2004-07-15 Vanderbil University Uso de inhibidores de calmodulin quinasa ii para tratar la disfuncion miocardica en la enfermedad de corazon estructural.
US7776925B2 (en) * 2002-03-06 2010-08-17 Duke University Reversing, postponing or preventing the occurrence of GTN tolerance and/or generation of reactive oxygen species from mitochondria
US7704954B2 (en) * 2003-05-01 2010-04-27 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
CA2947343C (en) * 2005-09-16 2019-04-30 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
CN107802821A (zh) * 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
CN105031605A (zh) * 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
US20110082084A1 (en) 2009-10-05 2011-04-07 Szeto Hazel H Methods for the prevention or treatment of heart failure
WO2011151359A1 (en) * 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248808A1 (en) * 2003-02-04 2004-12-09 Szeto Hazel H. Methods for preventing mitochondrial permeability transition
US20070027087A1 (en) * 2003-02-04 2007-02-01 Szeto Hazel H Methods for preventing mitochondrial permeability transition
WO2009100363A2 (en) * 2008-02-07 2009-08-13 Cornell University Methods for preventing or treating insulin resistance

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025044786A1 (zh) * 2023-08-28 2025-03-06 南京医科大学 一类肽及其衍生物和应用

Also Published As

Publication number Publication date
US11534476B2 (en) 2022-12-27
EP3120860A1 (en) 2017-01-25
US20210187056A1 (en) 2021-06-24
WO2011044044A1 (en) 2011-04-14
US20200188470A1 (en) 2020-06-18
JP2022046811A (ja) 2022-03-23
EP2764871A1 (en) 2014-08-13
US12102659B2 (en) 2024-10-01
JP7382607B2 (ja) 2023-11-17
US20230285499A1 (en) 2023-09-14
JP2020097627A (ja) 2020-06-25
CA2776581C (en) 2020-12-15
US20110082084A1 (en) 2011-04-07
EP2485749A1 (en) 2012-08-15
CN102711785A (zh) 2012-10-03
EP3603658A1 (en) 2020-02-05
EP3120860B1 (en) 2019-06-26
US20160106800A1 (en) 2016-04-21
JP7017762B2 (ja) 2022-02-09
JP2016190876A (ja) 2016-11-10
EP2944317A1 (en) 2015-11-18
US20140100166A1 (en) 2014-04-10
JP2018203764A (ja) 2018-12-27
JP2015163609A (ja) 2015-09-10
JP6429835B2 (ja) 2018-11-28
EP2485749A4 (en) 2013-07-24
CA2776581A1 (en) 2011-04-14
HK1217293A1 (en) 2017-01-06
US20180236025A1 (en) 2018-08-23
JP2013506696A (ja) 2013-02-28
EP3603658B1 (en) 2025-01-08

Similar Documents

Publication Publication Date Title
US12102659B2 (en) Methods for the prevention or treatment of heart failure
US20180104304A1 (en) Methods for preventing or treating metabolic syndrome
US20250319152A1 (en) Methods for the prevention or treatment of left ventricle remodeling
CN104725472A (zh) 芳香族阳离子肽及其用途
CN104922653A (zh) 治疗或预防哺乳动物对象中骨骼肌衰弱的方法
CN102791280A (zh) 用于预防或治疗血管阻塞损伤的方法
CN105407906A (zh) 预防或治疗巴斯综合征的方法和组合物
HK1176561A (en) Methods for the prevention or treatment of heart failure
HK1233532A1 (en) Methods for the prevention or treatment of cardiac fibrosis
HK1233532B (en) Methods for the prevention or treatment of cardiac fibrosis
HK1222794B (en) Methods for the prevention or treatment of left ventricle remodeling

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140611